T1, T2 Mapping and Extracellular Volume Fraction (ECV): Application, Value and Further Perspectives in Myocardial Inflammation and Cardiomyopathies

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 187, Issue 9, 2015, Pages 760-770

  Roller, F C ^a   Harth, S ^a   Schneider, C ^a   Krombach, G A ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

amyloidosis; cardiac; inflammation; MR imaging; technical aspects

Indexed keywords

AMYLOID; GADOBENATE DIMEGLUMINE;

AMYLOIDOSIS; ANDERSON FABRY DISEASE; ARTICLE; CARDIAC IMAGING; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONGESTIVE CARDIOMYOPATHY; EXTRACELLULAR SPACE; FABRY DISEASE; HEART MUSCLE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; MOLECULAR PATHOLOGY; MYOCARDITIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; TAKOTSUBO CARDIOMYOPATHY; TISSUE CHARACTERIZATION; ALGORITHM; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

ALGORITHMS; CARDIOMYOPATHIES; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MYOCARDITIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84940460431     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0034-1399546     Document Type: Article

References (75)

1. Achenbach S., Barkhausen J., Beer M. et al. Consensus recommendations of the German Radiology Society (DRG), the German Cardiac Society (DGK) and the German Society for Pediatric Cardiology (DGPK) on the use of cardiac imaging with computed tomography and magnetic resonance imaging. Fortschr Röntgenstr: 2012; 184 345 368
2. Kellman P., Arai A. E., Xue H. T1 and extracellular volume mapping in the heart: estimation of error maps and the influence of noise on precision. J Cardiovasc Magn Reson: 2013; 15 56
3. Kellman P., Hansen M. S. T1-mapping in the heart: accuracy and precision. J Cardiovasc Magn Reson: 2014; 16 2
4. Dass S., Suttie J. J., Piechnik S. K. et al. Myocardial tissue characterization using magnetic resonance non contrast T1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging: 2012; 6 726 733
5. Ferreira V. M., Piechnik S. K., DallArmellina E. et al. Non contrast T1 mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson: 2012; 14 42
6. Karamitsos T. D., Piechnik S. K., Banypersad S. M. et al. Non-contrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. J Am Coll Cardiol Img: 2013; 6 488 497
7. Sado D. M., White S. K., Piechnik S. K. et al. Identification and assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Non-contrast myocardial T1 mapping clinical perspective. Circ Cardiovasc Imaging: 2013; 6 392 398
8. Pedersen S. F., Thrys S. A., Robich M. P. et al. Assessment of intramyocardial hemorrhage by T1-weighted cardiovascular magnetic resonance in reperfused myocardial infarction. J Cardiovasc Magn Reson: 2012; 14 59
9. Iles L., Pfluger H., Phrommintikul A. et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol: 2008; 52 1574 1580
10. Chan W., Duffy S. J., White D. A. et al. Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion. J Am Coll Cardiol Img: 2012; 5 884 893
11. Ng A. C., Auger D., Delgado V. et al. Association between diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced T mapping and subclinical myocardial dysfunction in diabetic patients: a pilot study. Circ Cardiovasc Imaging: 2012; 5 51 59
12. Kellman P., Wilson J. R., Xue H. et al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson: 2012; 14 63
13. White S. K., Sado D. M., Fontana M. et al. T1 Mapping for Myocardial Extracellular Volume measurement by CMR: Bolus Only Versus Primed Infusion Technique. J Am Coll Cardiol Img: 2013; 6 955 962
14. Schelbert E. B., Testa S. M., Meier C. G. et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson: 2011; 4 13 16
15. Wong T. C., Piehler K., Meier C. G. et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation: 2012; 126 1206 1216
16. Thavendiranathan P., Walls M., Giri S. et al. Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 Mapping. Circ Cardiovasc Imaging: 2012; 5 102 110
17. Usman A. A., Taimen K., Wasielewski M. Resonance T2 Mapping in the monitoring and follow-up of acute cardiac transplant rejection: A Pilot Study. Circ Cardiovasc Imaging: 2012; 6 782 790
18. Messroghli D. R., Greiser A., Frohlich M. et al. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging: 2007; 26 1081 1086
19. Doolan A., Langlois N., Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust: 2004; 180 110 112
20. Felker G. M., Thompson R. E., Hare J. M. et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med: 2000; 342 1077 1084
21. Lauer B., Niederau C., Kuhl U. et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol: 1997; 30 1354 1359
22. Friedrich M. G., Strohm O., SchulzMenger J. et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation: 1998; 97 1802 1809
23. Mahrholdt H., Goedecke C., Wagner A. et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation: 2004; 109 1250 1258
24. Abdel-Aty H., Boye P., Zagrosek A. et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol: 2005; 45 1815 1822
25. Cooper L. T., Baughman K. L., Feldman A. M. et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol: 2007; 50 1914 1931
26. Friedrich S. G., Sechtem U., Schulz-Menger J. et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol: 2009; 53 17 1475 1487
27. Luetkens J. A., Doerner J., Thomas D. K. et al. Acute myocarditis: multiparametric cardiac MR imaging. Radiology: 2014; 273 383 392
28. Ferreira V. M., Piechnik S. K., DallAremellina D. et al. T1 Mapping for the Diagnosis of Acute Myocarditis Using CMR: Comparison to T2-Weighted and Late Gadolinium Enhanced Imaging. J Am Coll Cardiol Img: 2013; 6 1048 1058
29. Hinojar R., Foote L., Arroyo Ucar E. et al. Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. J Am Coll Cardiol Img: 2015; 8 37 46
30. Giri S., Chung Y. C., Merchant A. et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson: 2009; 11 56
31. Radunski U. K., Lund G. K., Stehning C. et al. CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging. J Am Coll Cardiol Img: 2014; 7 667 675
32. Bos J. M., Towbin J. A., Ackermann M. J. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol: 2009; 54 201 211
33. Seidman J. G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell: 2001; 104 557 567
34. Maron B. J., Gardin J. M., Fleck J. M. et al. Prevalence of hypertrophic cardiomyopathy in general population of young adults. Echocardiographic analysis of 4111 subjects in the cardia study. Coronary artery risk development in (young) adults. Circulation: 1995; 92 785 789
35. Decker J. A., Rosano J. W., Smith E. O. et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol: 2009; 54 250 254
36. Lu M., Zhao S., Yin G. et al. T1 mapping for detection of left ventricular myocardial fibrosis in hypertrophic cardiomyopathy: A preliminary study. Eur J Radiol: 2013; 82 225 231
37. Kwon D. H., Smedira N. G., Rodriguez E. R. et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol: 2009; 54 242 249
38. Prinz C., van Buuren F., Faber L. et al. Myocardial fibrosis is associated with biventricular dysfunction in patients with hypertrophic cardiomyopathy. Echocardiography: 2012; 29 438 444
39. Bongioanni S., Spirito P., Masi A. S. et al. Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features. Circ Cardiovasc Imaging: 2009; 2 349 350
40. OHanlon R., Grasso A., Roughton M. et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol: 2010; 56 867 874
41. Hoy C. JLB, Coehlo-Filho H., Lakdawala N. K. et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med: 2010; 363 552 563
42. Bruder O., Wagner A., Jensen C. J. et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol: 2010; 56 875 887
43. Kim R. J., Judd R. M. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? J Am Coll Cardiol: 2003; 41 1568 1572
44. Varnava A. M., Elliott P. M., Sharma S. et al. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart: 2000; 84 476 482
45. Iles L., Pfluger H., Phrommintikul A. et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol: 2008; 52 1574 1580
46. Sibley C. T., Noureldin R. A., Gai N. et al. T1 Mapping in Cardiomyopathy at Cardiac MR: Comparison with Endomyocardial Biopsy. Radiology: 2012; 265 724 732
47. Lu M., Zhao S., Yin G. et al. T1 mapping for detection of left ventricular myocardial fibrosis in hypertrophic cardiomyopathy: A preliminary study. Eur J Radiol: 2013; 82 225 231
48. Fang L., Beale A., Ellims A. H. et al. Associations Between Fibrocytes and Postcontrast Myocardial T1 Times in Hypertrophic Cardiomyopathy. J Am Heart Assoc: 2013; 2 e000270
49. Watkins H., Ashrafian H., Redwood C. Inherited Cardiomyopathies. N Engl J Med: 2011; 364 1643 1656
50. Towbin J. A., Bowles N. E. The failing heart. Nature: 2002; 415 227 233
51. Hoe C. J., Seidman C. E. A contemporary approach to hypertrophic cardiomyopathy. Circulation: 2006; 113 e858 e862
52. Assomull R. G., Prasad S. K., Lyne J. et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol: 2006; 48 1977 1985
53. Puntmann V. O., Voigt T., Chen Z. et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. J Am Coll Cardiol Img: 2013; 6 475 484
54. Kellman P., Wilson J. R., Xue H. et al. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. J Cardiovasc Magn Reson: 2012; 14 64
55. Nishii T., Kono A. K., Shigeru M. et al. Cardiovascular magnetic resonance T2 mapping can detect myocardial edema in idiopathic dilated cardiomyopathy. Int J Cardiovasc Imaging: 2014; 30 01 65 72
56. Banypersad S. M., Moon J. C., Whelan C. et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc: 2012; 1 e000364
57. Selvanayagam J. B., Hawkins P. N., Paul B. et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol: 2007; 50 2101 2110
58. Falk R. H. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation: 2011; 124 1079 1085
59. Austin B. A., Tang W. H., Rodriguez E. R. et al. Delayed hyper-enhancementmagnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. J Am Coll Cardiol Img: 2009; 2 1369 1377
60. Maceira A. M., Joshi J., Prasad S. K. et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation: 2005; 111 186 193
61. Maceira A. M., Prasad S. K., Hawkins P. N. et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson: 2008; 10 54
62. Syed I. S., Glockner J. F., Feng D. et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. J Am Coll Cardiol Img: 2010; 3 155 164
63. Fontana M., Banypersad S. M., Treibel T. A. et al. Native T1 Mapping in Transthyretin Amyloidosis. J Am Coll Cardiol Img: 2014; 7 157 165
64. MacDermot K. D., Holmes A., Miners A. H. Anderson-Fabry disease: clinicalmanifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet: 2001; 38 750e60
65. Hoey E. T., Neil-Gallagher E. Utility of gadolinium enhancedcardiovascular MRI to differentiate Fabrys disease from other causes of hypertrophic cardiomyopathy. Postgrad Med J: 2012; 88 1046 731 732
66. Eng C. M., Guffon N., Wilcox W. R. et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabrys disease. N Engl J Med: 2001; 345 9 16
67. Messalli G., Imbriaco M., Avitabile G. et al. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med: 2012; 117 19 28
68. Moon J. C., Sachdev B., Elkington A. G. et al. Gadolinium enhanced cardiovascularmagnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J: 2003; 24 2151e5
69. Ries M., Clarke J. T., Whybra C. et al. Enzyme-replacement therapy with agalisade alfa in children with Fabry disease. Pediatrics: 2006; 118 924e32
70. Collin C., Briet M., Tran T. C. et al. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease. Eur J Prev Cardiol: 2012; 19 43 54
71. Thompson R. B., Chow K., Khan A. et al. T mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging: 2013; 6 637 645
72. Sado D. M., Flett A. S., Banypersad S. M. et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart: 2012; 98 1436 1441
73. Wittstein I. S., Thiemann D. R., Lima J. A. et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med: 2005; 352 539 548
74. Abdel-Aty H., Cocker M., Friedrich M. G. Myocardial edema is a feature of Tako-Tsubo cardiomyopathy and is related to the severity of systolic dysfunction: insights from T2-weighted cardiovascular magnetic resonance. Int J Cardiol: 2009; 132 291 293
75. Aus dem Siepen F., Buss S. J., Messroghli D. et al. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur Heart J Cardiovasc Imaging: 2015; 16 210 216